UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Earliest Event Reported): June 7, 2016
CYTRX CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
000-15327
(Commission File Number)
|
58-1642740
(I.R.S. Employer Identification No.)
|
|
11726 San Vicente Boulevard, Suite 650
Los Angeles, California
(Address of Principal Executive Offices)
|
90049
(Zip Code)
|
(310) 826-5648
(Registrant's Telephone Number, Including Area Code)
______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 8.01 | Other Events |
At the Jefferies 2016 Healthcare Conference held in New York City on June 7, 2016, CytRx Corporation ("we," "our," "us," "CytRx," or the "company") will update our business information on our pivotal Phase 3 trial of aldoxorubicin as a therapy for patients with soft tissue sarcoma, or STS, whose tumors have progressed following treatment with chemotherapy, as follows:
|
·
|
We now expect to report top-line results on progression-free survival, or PFS, the trial's primary endpoint, in July 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CYTRX CORPORATION
|
|
|
Date: June 7, 2016
|
By: /s/ JOHN Y. CALOZ
|
|
Name: John Y. Caloz
|
|
|
Title: Chief Financial Officer
|
|